Qiagen Gets FDA Approval Of Therascreen KRAS RGQ PCR Kit

(RTTNews) - Qiagen N.V. (QGEN) announced that its therascreen KRAS RGQ PCR Kit has received U.S. Food and Drug Administration or FDA approval to guide the treatment of metastatic colorectal cancer patients with Amgen's Vectibix.

QIAGEN's growing menu of clinically validated companion diagnostics is driving global dissemination of personalized healthcare, which uses genomic information to guide treatment decisions in individual patients.

KRAS mutations, occurring in approximately 40% of colorectal cancer patients, influence response to anti-EGFR therapies such as Vectibix and Erbitux. Screening colorectal cancer patients with therascreen KRAS detects the most frequent mutations in the KRAS gene and helps to guide treatment planning.